Rosy  Wills

Rosy Wills

Followers 0
Following 0
According to the new market research report Immunoassay Market is projected to reach USD 39.0 billion by 2026 from USD 28.4 billion in 2021, at a CAGR of 6.6% during the forecast period.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=436Market growth is largely driven by the rising incidence of chronic and infectious diseases, technological advancements of immunoassay products, and their massive adoptions.Emerging markets in Asian countries are expected to offer strong growth opportunities for players in the market.In contrast, the stringent regulatory scenario and technical hurdles of the immunoassay products may restrict market growth to a certain extent.The immunoassay market is segmented based on product, technology, specimen, application, end user and region.The global immunoassay market is consolidated.With a wide distribution network across the globe and a strong product portfolio, it has established itself as one of the leading market players.The acquisition created its global science and technology innovator company, known as Cytiva.Thermo Fisher Scientific (US) is one of the leading players in the immunoassay market.
According to the new market research report global Diagnostic Electrocardiograph ECG Market is expected to reach USD 10.3 billion by 2024 from USD 7.5 billion in 2019, at a CAGR of 6.4% during the forecast period.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173The Factors such as the rising incidence of lifestyle & cardiovascular diseases and increasing geriatric population are expected to propel the growth of the market.Asia Pacific diagnostic ECG market is expected to grow at the highest CAGR during the forecast periodOn the basis of region, the diagnostic ECG market is segmented into North America, Europe, Asia Pacific, and RoW.The Asia Pacific is expected to grow at the highest CAGR during the forecast period.Factors such as growth in the geriatric population, growing incidence of chronic diseases, rising healthcare spending, healthcare reforms for infrastructural development, growing demand for advanced technologies, and less stringent regulations are fueling the demand for diagnostic ECG products and services in this region.The 3-lead ECG segment is expected to grow at the highest CAGR in the diagnostic ECG market during the forecast periodBy lead type, the diagnostic ECG market is divided into 12-lead, 5-lead, 3-lead, 6-lead, single-lead, and other lead types (15- and 18-lead).The 3-lead segment is expected to grow at the highest CAGR during the forecast period.This positive growth is primarily due to the fact that these leads are used conjointly with various other cardiac diagnostic tests and during medical procedures.The hospitals, clinics, and cardiac centers segment accounted for the largest share of the Diagnostic Electrocardiograph (ECG) Market in 2018By end user, the market is classified into hospitals, clinics, and cardiac centers; ambulatory surgical centers; and other end users.In 2018, the hospitals, clinics, and cardiac centers segment accounted for the largest share of the market.
According to the new market research report Stable Isotope Labeling Market is projected to grow at a CAGR of 3.0% during the forecast period to reach USD 312 million by 2024 from USD 269 million in 2019.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=53034199The growth of the Stable Isotope Labeling Market is driven majorly by the rising proteomics research, increase in research activities in the pharmaceutical and biotechnology sector, and the rising prevalence of cancer.In 2019, North America dominated the stable isotope labeled compounds market, followed by Europe.The major factors driving the growth of this market include the growth of the pharmaceutical and biopharmaceutical industry, the growth of the Canadian pharmaceutical industry, the large nuclear industry in the US and the availability of funding in North American countries.Based on application, the stable isotope labeled compounds market is segmented into research, clinical diagnostics, industrial applications, and other applications.The research segment accounted for the largest share of the stable isotope-labeled compounds market in 2019, owing to rising research activities in the biomedical, pharmaceutical, environmental & ecological, and agricultural sectors.Based on type, the stable isotope labeled compounds industry is segmented into C-13, N-15, O-18, H-2 (deuterium), and other isotopes.The H-2 labeled compounds segment accounted for the largest share of the stable isotope-labeled compounds market in 2019.The large share of this segment can be attributed to the increasing pharmaceutical research conducted using deuterium and the growing nuclear industry.
According to the new market research report Cardiac Monitoring Market is projected to reach USD 26.8 billion by 2025 from USD 22.1 billion in 2020, at a CAGR of 4.0% from 2020 to 2025.Ask for PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=55The growth of this market is driven by the increasing prevalence of cardiovascular diseases; availability of reimbursement for CM & CRM devices; launch of innovative products by market players; increasing investments, funds, and grants for research on CM & CRM devices; and the growing preference for wearable cardiac devices.The major players operating in this Cardiac Monitoring Market are Medtronic (Ireland), Boston Scientific (US), Abbott Laboratories (US), GE Healthcare (US), BIOTRONIK (Germany), and Koninklijke Philips (Netherlands), Asahi Kasei Corporation (Japan), MicroPort Scientific Corporation (China), Hill-Rom Holdings (US), Nihon Kohden (Japan), SCHILLER AG (Switzerland), BioTelemetry (US), BPL Medical Technologies (India), ACS Diagnostics (US), Shenzhen Mindray Bio-Medical Electronics (China), Lepu Medical Technology (China), Shree Pacetronix (India), OSYPKA (Germany), and BTL t(US), Alivecor, Inc. (US), Amiitalia (Italy), Bexen Cardio (Spain), Narang Medical Limited (India), MeTrax GmbH (Germany), and Progetti Srl (Italy).On the basis of region, the Cardiac Monitoring Market is segmented into North America, Europe, Asia Pacific, and Rest of the World.In 2019, North America commanded the largest share of the market.The large share of this market segment can be attributed to the increasing incidence of CVD, increasing healthcare expenditure, growing disposable income, growing healthcare awareness, and the availability of technologically advanced devices in the region.On the basis of cardiac rhythm management devices by type, the market is segmented into defibrillators and pacemakers.In 2019, the defibrillators segment accounted for the largest market share.This segment is also projected to register the highest CAGR during the forecast period.Factors such as technological advancements in defibrillators, rising prevalence of CVD, and growing focus on providing public-access defibrillators are driving the growth of this market.By end user, the cardiac rhythm management devices market is segmented into hospitals; clinics, cardiac centers, and ambulatory surgery centers (ASCs); and other end users.
Market growth influenced due to following factors-Rising incidences of infectious diseases (such as HIV, tuberculosis, and malaria) and genetic disorders.Continuous technological advancements in PCR technologies and the commercialization of lab-on-chip devices and microfluidics-based portable instruments.Increasing investments, funds, and grants for genomic research.Increasing use of biomarker profiling for disease diagnostics.Global market size-According to research report the dPCR and qPCR market is projected to reach $7.6 billion by 2025, at a CAGR of 9.0% between 2020 and 2025.Leading Players & Growth Strategies -The major players operating in the dPCR and qPCR market include Thermo Fisher Scientific, Inc. (US), Takara Bio, Inc. (Japan), Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (US), Fluidigm Corporation (US), bioMérieux S.A. (France), Danaher Corporation (US), Merck KGaA (Germany), Becton Dickinson and Company (US), Eppendorf AG (Germany), Promega Corporation (US), and Analytik Jena AG (Germany).Top Market Segments -Based on products & services, the market is categorized into reagents and consumables, instruments and software & services.The qPCR reagents and consumables segment is expected to command the largest share of the qPCR products & services market in 2020, owing to the factors such as the expanding applications of qPCR (owing to its technological benefits over traditional PCR, such as real-time analysis and reduced analysis time), growing private-public funding for life science research, and the rising number of probe-based multiplex genetic analysis proceduresBased on application, the market is categorized into clinical applications (Infectious Disease Testing, Oncology Testing, Blood Screening, Transplant Diagnostics and Other Clinical Applications), research applications and forensic applications.The clinical applications segment is estimated to dominate the qPCR applications market in 2020.For More Details, Download PDF BrochureGeographic Overview -North America accounted for the largest share of the dPCR and qPCR market, followed by Europe in 2019.The large share of the North American regional segment can be attributed to the increased adoption of innovative and novel genomic analysis products (including advanced qPCR and dPCR products), availability of R funding for genomic research (coupled with the robust research infrastructure in the region), expanding use of PCR techniques in clinical diagnostics & forensics, and early commercialization of qPCR/dPCR products compared to other regions.
According to research report the cancer biomarkers market to reach USD 20.4 billion by 2022. and is estimated to grow at a CAGR of 12.2% during the forecast period.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202The increasing prevalence of cancer, rising government support for research on cancer biomarkers, growing use of biomarkers in drug discovery and development, and increasing use of biomarker tests for diagnostic purposes are the major factors that are driving the growth of this market.North America accounted for the largest share of the cancer biomarkers market in 2017, followed by Europe.North America is the largest market for cancer biomarkers majorly due to government support (in the US and Canada) for the discovery and development of biomarkers, rising use of biomarkers in drug discovery and development by pharmaceutical companies, adoption of advanced omics technologies for biomarker discovery, and the increasing demand for personalized medicine in the region.Based on cancer type, the cancer biomarkers market is segmented into breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-Hodgkins lymphoma, kidney, and other cancers (such as cervical, multiple myeloma, CNS, gastric, liver, pancreatic, oral cavity and pharynx, stomach, and ovarian cancers).The breast cancer segment accounted for the largest share of this market owing to the high and growing prevalence of breast cancer, increasing awareness about breast cancer, rising number of breast cancer screening programs, and growing research on breast cancer.Based on biomarker type, the cancer biomarkers market is segmented into genetic biomarkers, protein biomarkers, and other biomarkers (cell, viral, and carbohydrate biomarkers).During the forecast period, the genetic biomarkers segment is estimated to grow at the highest CAGR majorly due to advancements in high-throughput technologies, such as next-generation sequencing, which have enhanced the speed and accuracy of genetic biomarker discovery and diagnosis.Request For Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=202The major players operating in the cancer biomarkers market are Abbott (US), Affymetrix (US), Roche (Switzerland), Illumina (US), QIAGEN (Netherlands), Agilent (US), Thermo Fisher (US), Merck (US), Becton Dickinson and Company (US), and Hologic (US).Contact:Mr. Aashish MehraMarketsandMarkets™ INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: [email protected]
According to the new market research report In Vitro Toxicity Testing Market is expected to reach USD 14.9 billion by 2025 from an estimated USD 9.1 billion in 2020, at a CAGR of 10.3%.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209577065Due to covid-19 outbreak, there has been a significant increase in Covid-19 testing and drug research.The research in this area is being further undertaken to understand the dynamics of the infection better, which is expected to propel the in vitro toxicology research field further.On the other hand, we are estimating that the major share of diagnostic assays and molecular testing of Covid-19, along with personalized medicine will grow at a stable pace in the next five years.There is a huge increase of manufacturers that have taken key steps to increase patient access to coronavirus diagnostic testing, vaccine and drug development in laboratories, hospitals, and other testing sites across the country to guide patient care and protect public health.The major factors driving the growth of this in vitro toxicity testing market are the opposition to animal testing, technological advancements, and increasing R expenditure to detect toxicity at an early stage during drug development are the primary growth drivers for this market.In the toxicity endpoints and tests market, the organ toxicity segment is expected to grow at the highest CAGR during the forecast periodThe organ toxicity segment is expected to grow at the highest CAGR during the forecast period.The growth in this segment can be attributed to factors such as the increasing focus on drug safety and consumer-product safety, along with the need to screen potential drug targets during the early stage of drug development.Based on the technologies used in the in vitro toxicology testing, the cell culture technologies segment is expected to account for the largest share of the in vitro toxicology testing marketThe cell culture technologies segment is estimated to account for the largest market share in 2018.The large share of this segment can be attributed to the fact that it is the most preferred technique for toxicity testing, being capable of mimicking in vivo conditions.By product and service, the consumables segment is expected to account for the largest share of the in vitro toxicity testing marketThe consumables segment is estimated to account for the largest market share in 2019.
According to research report the IVD Quality Control Market is projected to reach $1,158 million by 2025 from $961 million in 2020, at a CAGR of 3.8% during the forecast period.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198032582 Some of the factors driving the growth of the In Vitro Diagnostics Quality Control Market are increasing number of accredited clinical laboratories, rising demand for external quality assurance support, and growing adoption of third-party quality controls.Based on applications, the IVD quality control market is segmented into clinical chemistry, immunochemistry, hematology, coagulation & hemostasis, microbiology, molecular diagnostics, and other applications (ESR, urine chemistry, immunology, cardiac assessment, and blood morphology).This growth can be attributed to the rising prevalence of infectious diseases, cancer, and various genetic disorders; the growing demand for blood screening; and the increasing application of molecular diagnostic technologies in pharmacogenetics and point-of-care testing.The serum/plasma based quality control segment is expected to dominate the market in 2019.The large share of this segment is mainly attributed to the greater uptake of serum/plasma-based quality controls among laboratories and the widening application areas of these controls for various IVD tests.
According to the new market research report Defibrillators Market is projected to reach USD 11.7 billion by 2025 from USD 9.6 billion in 2019, growing at a CAGR of 3.4% during the forecast period.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=549The growth in this market is driven by the rising prevalence of target diseases, growing focus on providing public-access defibrillators, and training and awareness programs on defibrillators.In addition, emerging markets and the development of S-ICDs and MRI-compatible ICDs and CRT-Ds are expected to offer growth opportunities for players in the defibrillators market.However, issues related to the use of implantable and automated external defibrillators, frequent product recalls, and a lack of awareness about sudden cardiac arrest in developing nations are expected to hinder the growth of the defibrillators market during the forecast period.The ICDs segment accounted for the largest share of the defibrillators market in 2019On the basis of type, the defibrillators market is segmented into implantable cardioverter defibrillators (ICDs) and external defibrillators.The external defibrillators market is further segmented into manual and semi-automated external defibrillators, fully automated external defibrillators, and wearable cardioverter defibrillators (WCDs).The ICDs segment accounted for the largest share of the defibrillators market in 2019.Factors such as the development of technologically advanced devices with extended longevity, rapid growth in the number of implant procedures, and increasing adoption of cardiac resynchronization therapy defibrillators (CRT-Ds) and S-ICD systems across the globe are contributing to the large share of this segment.The hospitals, clinics, and cardiac centers segment accounted for the largest share of the global defibrillators market in 2019On the basis of end users, the defibrillators market is segmented into hospitals, clinics, and cardiac centers; prehospital care settings; public access markets; alternate care facilities; and home care settings.
According to the new market research report Single use Bioreactors Market is projected to reach USD 3.9 billion by 2025 from USD 1.7 billion in 2020, at a CAGR of 18.0% during the forecast period.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=49113750Increasing adoption of SUBs among small companies and startups, technological advancements in SUBs, reduced automation complexity, ease in the cultivation of marine organisms, reduced energy and water consumption, the growing biologics market and increasing Biopharmaceutical R are factors driving the growth of this market.Based on product, the Single use Bioreactors Market is categorized into single-use bioreactor systems, single-use media bags, single-use filtration assemblies, and other products such as single-use vessels, tubing, connectors, control systems, and probes/sensors, among others.The single-use bioreactor systems segment dominated the market in 2019.SUB systems offer benefits such as lower capital investment, lower operating expenses, and lower environmental footprint, thus driving the growing adoption of these systems in biopharma applications.Opportunity: Emerging marketsThe significant growth opportunities offered by emerging countries such as China, India, and Indonesia can be attributed to high growth in their respective pharmaceutical & biopharmaceutical sectors due to the presence of less-stringent regulatory policies as well as low-cost and skilled labor.Owing to cost advantages and skilled labor, these countries are a hub for bioprocess outsourcing.Developing countries are showing faster growth rates in single-use systems.
Global market size-According to the new market research report eHealth Market is expected to reach $193.8 billion by 2025, at a CAGR of 22.8% during the forecast period.Market growth influenced due to following factors-Growing need to manage regulatory compliance through the use of eHealth solutions.The need to curtail escalating healthcare costs.Increasing government initiatives supporting the use of eHealth solutions and services.Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=11513143Leading Players-The players in the eHealth market include Allscripts (US), athenahealth (US), Epic Systems (US), IBM (US), GE Healthcare (US), Cerner (US), Optum (US), Philips (Netherlands), Siemens Healthineers (Germany), McKesson (US), Medtronic (Ireland), and Cisco Systems (US).Top Market Segments-By type of eHealth solutions market, the chronic care management apps are expected to register the highest CAGR during the forecast period.This can be attributed to the growing incidence of chronic diseases, high penetration of mobiles, and increasing adoption of mHealth solutions owing to various benefits such as ease of use and reduced costs offered by these solutions across the globe.Based on type of eHealth services market, the remote monitoring services segment is expected to register the highest CAGR during the forecast period.Opportunity:In response to the rising pressures on health systems to lower the cost of care, a majority of healthcare organizations are focusing on introducing specialized outpatient services.The shift toward the outpatient care model is boosting the adoption of eHealth solutions, as these solutions provide a convenient way of care delivery.These solutions provide easier access to appointments and integration among care providers for holistic response toward care delivery.In addition, these solutions help physicians in addressing patient needs (for access) and allow the remote monitoring of the patient’s health.
According to market research report the global Coagulation Analyzer Market is projected to reach USD 5.0 billion by 2025 from USD 3.8 billion in 2020, at a CAGR of 5.7% between 2020 and 2025.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197226392 Increasing prevalence of cardiovascular diseases and blood disorders and the rising geriatric population are expected to boost the growth of this market in the coming years.Emerging economies such as Brazil, India and China are expected to provide a wide range of opportunities for players in the industry.Clinical laboratories dominated the Coagulation Analyzer Market in 2019 On the basis of end user, the Hemostasis Analyzer Market is segmented into clinical laboratories, hospitals, and other end users.In 2019, the clinical laboratories segment accounted for the largest share of the market.Clinical laboratory analyzers dominated the Coagulation Analyzer Market in 2019 Based on product, the Hemostasis Analyzer Market is segmented into clinical laboratory analyzers and point-of-care testing analyzers.
According to the market research report Optical Imaging Market is projected to reach USD 3.3 billion by 2026 from USD 1.6 billion in 2021, at a CAGR of 14.8% during the forecast period.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=894Optical imaging is a rapidly developing field that has significantly impacted the global healthcare industry by facilitating effective and affordable healthcare.Factors such as the increasing research & development activities in the life sciences sector, rising aging population and increasing applications of optical imaging techniques in drug discovery processes and preclinical research are fueling the growth of this market.Based on technique, the optical imaging market is broadly categorized into optical coherence tomography (OCT), hyperspectral imaging (HIS), near-infrared spectroscopy (NIRS), and photoacoustic tomography (PAT).The OCT technique commanded the largest share of the global optical imaging system market; this segment will continue to dominate the global optical imaging market by 2026.The large share of this market can be attributed to its wide acceptance for research and clinical diagnostics in ophthalmology, oncology, cardiology, dermatology, neurology, and other clinical areas.Based on products, the optical imaging market is divided into imaging systems, cameras, software, lenses, illumination systems, and others.The imaging systems segment dominated the optical imaging system market in 2020.
According to research report the global X-Ray Detectors Market is projected to reach USD 3.8 billion by 2024 from USD 2.8 billion in 2019, at a CAGR of 6.1% during the forecast period.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=7004984Factors such as declining prices and benefits offered by digital detectors, growing public and private investments in Digital Imaging technologies and reimbursement cuts for analog X-rays are driving the growth of the X-ray detectors market.Based on type, the market is segmented into flat-panel detectors (FPDs), computed radiography (CR) detectors, charge-coupled device (CCD) detectors, and line-scan detectors.In 2019, the flat-panel detectors segment is expected to account for the largest share of the X-ray detectors market.The growth in this market is mainly driven by the advantages offered by FPD-based portable digital systems (such as high-quality images, faster scanning, increased patient throughput, and multiple storage options), their decreasing prices, and the growing demand for retrofit FPD-based digital X-ray systems.By application, the market is segmented into medical, dental, security, veterinary, and industrial applications.The medical applications segment is expected to grow at the highest rate during the forecast period.The growth in this segment can primarily be attributed to the advancements in medical technology, rising geriatric population, and the increasing number of orthopedic and cardiovascular procedures.In 2019, North America is expected to account for the largest share of the X-ray detectors market, followed by Europe, Asia, and the RoW.The large share of this region is attributed to factors such as availability of venture capital and government funding, technological innovations, increasing healthcare spending and increasing incidence of chronic diseases.Data TriangulationAfter arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.
According to the new market research report Spirometer Market is projected to reach USD 1,285 million by 2025 from USD 799 million in 2020, at a CAGR of 11.1%.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=18015659The rising global incidence of respiratory diseases, increasing aging population, and the technological shift in spirometer devices towards smartphone-based data acquisition are the key factors driving the growth of this market.The spirometer market has been segmented based on product, mechanism, application, end user and region.Based on product, the spirometer market is segmented into devices, consumables & accessories, and software.This segment is expected to witness the highest growth rate during the forecast period.The rising incidence of respiratory diseases and the growing geriatric population are the key factors driving the growth of this product segment.Based on mechanism, the spirometer market is segmented into flow-sensing spirometer and peak flow meters.The flow- sensing segment accounted for the highest share in 2019.The rising incidence of chronic respiratory diseases and technological advancements are driving the growth of this segment.Based on end user, the Spirometry Market is segmented into hospitals, clinical laboratories, home care settings, and industrial settings.Rapidly growing aging population, the increase in reimbursements for clinical tests performed in hospitals, and the launch of advanced spirometer devices are the factors driving the growth to this market during the forecasted period.
According to research report the Lab Informatics Market is estimated to reach USD 3.8 billion by 2024 from USD 2.6 billion in 2019, at a CAGR of 7.5% during the forecast period.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=203037633Growth in this market is mainly driven by the increasing need for laboratory automation, increasing need to comply with regulatory standards, development of integrated lab informatics solutions and the growing demand in biobanks/biorepositories.The pharmaceutical & biotechnology companies segment accounted for the largest share of the life sciences industry market in 2018.The life sciences industry is further segmented into pharmaceutical & biotechnology companies, biobanks & biorepositories, contract service organizations (CROs & CMOs), molecular diagnostics & clinical research laboratories, and academic research institutes.Based on components, the laboratory informatics market is segmented into services and software.The services segment dominated the Lab Informatics Market in 2018.The large share of the services segment can be attributed to the growing technological advancements in solution offerings by various vendors, increasing adoption of cloud-based solutions, growing need for consulting services, and the recurring nature of services.Furthermore, in terms of IT usage and skill, the life science industry relies heavily on service providers.Opportunity: Growing popularity of cloud-based laboratory informaticsThe emergence of cloud-based services via the Internet has led to significant advances in the laboratory informatics market.Advances in virtualization and improved access to high-speed internet offer faster innovation, often at lower costs.
According to the new market research report Clinical Microbiology Market is estimated to be USD 3.9 billion in 2020 and projected to reach USD 5.3 billion by 2025, at a CAGR of 6.5%.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=219135367The global microbiological testing market offers significant growth potential for prominent as well as emerging product manufacturers.The clinical microbiology market includes major Tier I and II suppliers like bioMérieux (France), Danaher Corporation (US), Becton, Dickinson and Company (US), Abbott Laboratories (US), and Roche Diagnostics (Switzerland).These suppliers have their manufacturing facilities spread across regions such as North America and Europe.COVID-19 has impacted their businesses as well.Demand for clinical microbiology from key end-users has declined a bit amidst the global COVID-19 pandemic.Industry experts believe that COVID-19 will have a short-term decline in the growth for the clinical microbiology market in 2020, but will experience normal development as the market gradually steadies by the end of 2020.Reagent estimated to be the growing marketThe clinical microbiology reagents market is expected to witness sustained demand during the forecast period, owing to the high prevalence of infectious diseases across major markets (resulting in a growing number of clinical diagnostic procedures), the increasing trend of reagent rental agreements along with instrument sales, and a growing number of life science researches in the field of specific reagents for targeted infectious disease diagnosis and treatment, especially across emerging countries.
SummaryMajor factors influencing the growth of the market.Leading players & Top Segments.Geographic Overview.Market growth influenced due to following factors-Growing cardiovascular and respiratory diseases,Rising adoption of ECMO as a bridge to heart & lung transplantation,Growing number of ECMO centers & conferences and training programs toIncrease awareness, and technological advancements are the significant factors driving the growth of this marketGlobal market size-According to the market research report ECMO machine market is expected to reach $ 305.3 Million by 2021, at a CAGR of 4.3%.These companies together contributed about 68.8% to the global market in 2015.The other players in the market are XENIOS AG (Germany), Terumo Corporation (Japan), MicroPort Scientific Corporation (China), NIPRO Corporation (Japan), OriGen Biomedical, Inc. (U.S.), ALung Technologies, Inc. (Germany), and EUROSETS S.r.l.Top Market Segments-Based on the modality, the ECMO machine market is segmented into venoarterial (VA), venovenous (VV), and arteriovenous (AV).The venovenous (VV) segment is estimated to account for the largest share of the global market in 2016, and venoarterial (VA) segment is projected to grow at the highest CAGR in the forecast period.Based on application, the ECMO machine market is segmented into Respiratory, Cardiac, and Extracorporeal Cardiopulmonary Resuscitation (ECPR).
According to research report wearable healthcare devices market size is projected to reach USD 46.6 billion by 2025 from USD 18.4 billion in 2020, at a CAGR of 20.5% from 2020 to 2025.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=81753973Emerging economies such as China, India and Brazil are expected to provide a wide range of opportunities for players in the market.Furthermore, increasing adoption of AI and 5G, growing adoption of mobile platforms, and the growing awareness and preference for home healthcare will also boost the growth of this market.The major players in the wearable healthcare devices market are Medtronic plc.(Ireland), Koninklijke Philips N.V. (Netherlands), OMRON Corporation (Japan), Biotelemetry Inc.(US), Apple, Inc. (US), Dexcom Inc. (US), Abbott Laboratories(US), CONTEC Medical Systems Co. Ltd (China), Biotricity Inc.(US), Verily Life Sciences.(US), Masimo Corporation(US), GE Healthcare(US), Bio-Beat Technologies (Israel), iRhythm Technologies, Inc. (US), VitalConnect (US), Minttihealth (US), Preventice Solutions, Inc. (US), Cyrcadia Asia Limited (Hong Kong ), ten3T healthcare (India), Fitbit, Inc. (US), Garmin Ltd (Switzerland), Xiaomi Technologies (China), and Huawei Corporation (China).Recent Developments:> In 2019, Apple Watch Series 5 was launched with advanced functionalities by Apple, Inc. (US)> In 2020, Fitbit Charge 4, activity tracker was launched by Fitbit, Inc. (US)> In 2019, Omron (Japan) launched HeartGuide, a wearable blood pressure smart watch.In 2019, the general health and fitness segment accounted for the largest share of the market, primarily due to the increasing focus on physical fitness among people to improve their quality of life, coupled with the growing trend of tracking health progress on a continuous basis.Based on device type, the wearable medical devices market is segmented into diagnostic & monitoring devices and therapeutic devices.In 2019, the diagnostic & monitoring devices segment accounted for a larger share of 64.3% of the wearable medical devices market.
According to the new market research report the Spinal Implants Devices Market is projected to reach USD 13.8 billion by 2025 from USD 10.3 billion in 2019, at a CAGR of 5.0%.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=712This market is primarily driven by the launch of advanced bone grafting products, the advancements in spine surgery technologies, increasing incidence of spinal disorders and the increasing adoption of minimally invasive spine surgeries.Based on product, the market is segmented into thoracic fusion and lumbar fusion devices, cervical fusion devices, spine biologics, non-fusion devices, vertebral compression fracture treatment devices, spinal decompression devices, and spine bone stimulators.The thoracic fusion and lumbar fusion devices segment accounted for the largest share of the market in 2019.The large share of this segment can be attributed to the increasing incidence of lumbar degenerative disc disease and the growing number of product launches.Based on the type of surgery, the market is segmented into open and minimally invasive surgeries.The open surgeries segment accounted for the largest share of the Spinal Surgery Devices Market in 2019.The large share of this segment can be attributed to the increasing preference for open spine surgeries among medical professionals, rising incidence of spinal deformities, and technological advancements in spinal fusion surgeries.In addition, some spine procedures, such as spinal implant insertions, can only be done through open surgeries, which is another major factor supporting market growth.On the basis of technology, the Spinal Surgery Devices Market is segmented into spinal fusion and fixation, vertebral compression fracture treatment, motion preservation/non-fusion, and spinal decompression technologies.
More

Top